Holly M Bastian
Overview
Explore the profile of Holly M Bastian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
775
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pons-Estel G, Alarcon G, McGwin Jr G, Danila M, Zhang J, Bastian H, et al.
Arthritis Rheum
. 2009 May;
61(6):830-9.
PMID: 19479701
Objective: To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients. Methods: Lupus nephritis patients (n = 256) from the LUpus in MInorities, NAture versus nurture study...
2.
Fernandez M, McGwin Jr G, Andrade R, Bastian H, Fessler B, Reveille J, et al.
J Clin Rheumatol
. 2008 Jun;
14(3):178-80.
PMID: 18525440
No abstract available.
3.
Fernandez M, Calvo-Alen J, Bertoli A, Bastian H, Fessler B, McGwin Jr G, et al.
J Clin Rheumatol
. 2007 Oct;
13(5):261-5.
PMID: 17921793
Objectives: To examine the influence of hormone replacement therapy (HRT) in the occurrence of vascular arterial and venous thrombotic events in postmenopausal women with systemic lupus erythematosus (SLE). Patients And...
4.
Alarcon G, McGwin G, Bertoli A, Fessler B, Calvo-Alen J, Bastian H, et al.
Ann Rheum Dis
. 2007 Mar;
66(9):1168-72.
PMID: 17389655
Objective: In patients with systemic lupus erythematosus (SLE), hydroxychloroquine prevents disease flares and damage accrual and facilitates the response to mycophenolate mofetil in those with renal involvement. A study was...
5.
Vila L, Alarcon G, McGwin Jr G, Bastian H, Fessler B, Reveille J
Arthritis Rheum
. 2006 Oct;
55(5):799-806.
PMID: 17013840
Objective: To determine if lymphopenia is associated with clinical/immunologic manifestations, disease activity, and disease damage in systemic lupus erythematosus (SLE). Methods: The study group comprised 591 patients with SLE participating...
6.
Vila L, Alarcon G, McGwin Jr G, Bastian H, Fessler B, Reveille J
J Rheumatol
. 2005 Nov;
32(11):2150-5.
PMID: 16265693
Objective: To determine if different categories of erythrocyte sedimentation rate (ESR) elevation are associated with disease activity and/or damage in systemic lupus erythematosus (SLE). Methods: We studied 2317 study visits...
7.
Calvo-Alen J, Toloza S, Fernandez M, Bastian H, Fessler B, Roseman J, et al.
Arthritis Rheum
. 2005 Jun;
52(7):2060-8.
PMID: 15986376
Objective: Venous thrombosis is a relatively frequent and serious complication in systemic lupus erythematosus (SLE) that has been associated with the presence of antiphospholipid antibodies (aPL). However, venous thrombotic events...
8.
Fernandez M, Calvo-Alen J, Alarcon G, Roseman J, Bastian H, Fessler B, et al.
Arthritis Rheum
. 2005 Jun;
52(6):1655-64.
PMID: 15934092
Objective: To determine the differences in clinical manifestations, disease activity, damage accrual, and medication use in systemic lupus erythematosus (SLE) patients as a function of menopausal status at disease onset....
9.
Fessler B, Alarcon G, McGwin Jr G, Roseman J, Bastian H, Friedman A, et al.
Arthritis Rheum
. 2005 May;
52(5):1473-80.
PMID: 15880829
Objective: To examine whether hydroxychloroquine (HCQ) usage is associated with a reduced risk of damage accrual in patients with systemic lupus erythematosus (SLE). Methods: Patients (n = 518) meeting the...
10.
Toloza S, Uribe A, McGwin Jr G, Alarcon G, Fessler B, Bastian H, et al.
Arthritis Rheum
. 2004 Dec;
50(12):3947-57.
PMID: 15593203
Objective: To determine the baseline (time 0) risk factors associated with the subsequent occurrence of vascular events in a multiethnic US cohort (LUMINA [LUpus in MInorities: NAture versus nurture]) of...